Healthcare medical costs among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) managed with systemic therapy following CDK 4/6 inhibitor (CDKi) in the real-world setting.
2018 ◽
Vol 36
(15_suppl)
◽
pp. 1067-1067
2020 ◽
2015 ◽
Vol 31
(8)
◽
pp. 1573-1582
◽
2015 ◽
2020 ◽
2018 ◽
Vol 34
(9)
◽
pp. 1645-1652
◽